In PLoS ONE Carlijn Hooijmans and colleagues describe how the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, the most widely used framework to rate the certainty in the evidence and strength of health care recommendations, could be used to rate the certainty in the evidence of preclinical animal studies in the context of therapeutic interventions.Laboratory animal studies are used in a wide range of human health related research areas, such as basic biomedical research, drug research, experimental surgery and environmental health. The results of these studies can be used to inform decisions regarding clinical research in humans, for example the decision to proceed to clinical trials. If the research question relates to potential harms with no expectation of benefit (e.g., toxicology), studies in experimental animals may provide the only relevant or controlled data and directly inform clinical management decisions. Systematic reviews and meta-analyses are important tools to provide robust and informative evidence summaries of these animal studies. Rating how certain we are about the evidence could provide important information about the translational probability of findings in experimental animal studies to clinical practice and probably improve it. Evidence summaries and certainty in the evidence ratings could also be used (1) to support selection of interventions with best therapeutic potential to be tested in clinical trials, (2) to justify a regulatory decision limiting human exposure (to drug or toxin), or to (3) support decisions on the utility of further animal experiments. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach is the most widely used framework to rate the certainty in the evidence and strength of health care recommendations. Here we present how the GRADE approach could be used to rate the certainty in the evidence of preclinical animal studies in the context of therapeutic interventions. We also discuss the methodological challenges that we identified, and for which further work is needed. Examples are defining the importance of consistency within and across animal species and using GRADE's indirectness domain as a tool to predict translation from animal models to humans.
Carlijn Hooijmans is assistant professor within the theme of Cancer development and immune defense
Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies. Hooijmans CR, de Vries RBM, Ritskes-Hoitinga M, Rovers MM, Leeflang MM, IntHout J, Wever KE, Hooft L, de Beer H, Kuijpers T, Macleod MR, Sena ES, Ter Riet G, Morgan RL, Thayer KA, Rooney AA, Guyatt GH, Schünemann HJ, Langendam MW; GRADE Working Group. PLoS One. 2018 Jan 11;13(1):e0187271.
SYstematic Review Center for Laboratory animal Experimentation
Related news items
Large AI project receives over €95 million for ten years of public-private research23 September 2021
Radboud university medical center (Radboudumc) participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboud university medical center leads five of these eight labs.read more
Reading ADP-ribosylation signaling using chemical biology and interaction proteomics published in Molecular Cell22 September 2021
Kasia Kliza and Michiel Vermeulen worked on a project to synthesize biotinylated ADPr-based probes that can identify ADPr readers and determine their specificity for mono- and polyADPr. They published this in Molecular Cell.read more
Systematic analysis of short tandem repeats in 38,095 exomes provides an additional diagnostic yield22 September 2021
Christian Gilissen and colleagues published in Genetics in Medicine about their work guiding the application of short tandem repeat analysis in clinical exome sequencing.read more
New start-up Patholyt will bring AI research into pathology diagnostics21 September 2021
Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.read more